Evidence map›Paper›PMID 32348107›Full record

ArticleACS chemical biology2020

Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids.

Zeyu Lu, Brenton R Paolella, Nicholas L Truex, Alexander R Loftis, Xiaoli Liao, Amy E Rabideau, Meredith S Brown, John Busanovich, Rameen Beroukhim, Bradley L Pentelute

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Genes · 2023
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Zeyu LuDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Brenton R PaolellaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02139, United States.
Nicholas L TruexDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-7369-685X
Alexander R LoftisDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Xiaoli LiaoDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Amy E RabideauDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
Meredith S BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02139, United States.
John BusanovichDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02139, United States.
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02139, United States.
Bradley L PenteluteDepartment of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.ORCID 0000-0002-7242-801X
Massachusetts Institute of Technology · USDana-Farber Cancer Institute · USBroad Institute · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KASPER, DENNIS L. · 2003 to 2013
$113.7M
Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Cytosolic Delivery of Tumor Antigens into Dendritic CellsF32CA239362 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI TRUEX, NICHOLAS L · 2020 to 2022
$179k
Cancer Specific Sensitivity to Suppression of Spliceosome ComponentsF32CA180653 · NCI · DANA-FARBER CANCER INST · PI PAOLELLA, BRENTON ROBERT · 2014 to 2017
$148k
NCI NIH HHS F32 CA180653NCI NIH HHS F32 CA239362NCI NIH HHS R01 CA188228NIAID NIH HHS U54 AI057159
6 · The paper itself

Abstract

Antisense oligonucleotide therapies are important cancer treatments, which can suppress genes in cancer cells that are critical for cell survival.

Indexed as

Antigens, BacterialBacterial ToxinsCell Line, TumorCell SurvivalDrug CarriersDrug Delivery SystemsGenetic TherapyHumansNeoplasmsOligonucleotides, AntisensePeptide Nucleic AcidsPhosphoproteinsRNA Splicing Factorsanthrax toxinAntigens, BacterialBacterial ToxinsDrug CarriersOligonucleotides, AntisensePeptide Nucleic AcidsPhosphoproteinsRNA Splicing FactorsSF3B1 protein, human

Identifiers

PMID32348107
PMCPMC7521945
OpenAlexW3018280397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.